Literature DB >> 31054106

Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review.

Alejandro Recio-Boiles1, Hytham Hammad2, Krisha Howell3, Bobby T Kalb4, Valentine N Nfonsam5, Aaron J Scott6, Hani M Babiker6, Emad Elquza6.   

Abstract

PURPOSE: An accurate clinical and radiological staging is the pyramid of treatment decisions in locally advanced rectal cancer (LARC). Guidelines recommended neoadjuvant chemoradiation therapy (CRT) followed by surgical resection for fit patients with LARC. Determining the aggressiveness of intervention while avoiding needless morbidity according to patient risk remains an unmet pre-operative decision-making need. With newer magnetic resonance imaging (MRI) techniques and image acquisition available at our Cancer Center, we seek to retrospectively review the correlation between pre- and post-CRT MRI response to the surgical pathological stage in order to aide multidisciplinary team decision making.
METHODS: Our Cancer Center Rectal Cancer Registry between 2011 and 2015 included 57 patients with LARC, 20 completed standard CRT with surgery, and of those 10 had repeated MRI after CRT.
RESULTS: Our retrospective case series revealed that 90% of the patients had a downstage tumor response on surgical specimen compared to radiological evaluation after CRT, and furthermore, all patients who were re-staged with MRI prior to surgery correlated with the gold standard pathological stage (p = 0.02).
CONCLUSIONS: Post-CRT MRI could potentially aide decision making to further avoid 20% of patients with a complete pathological response from a morbid surgery, whereas 10% of patients with an upstaged disease state may require a more aggressive neoadjuvant or planned surgical intervention. We concluded that future multidisciplinary oncology care treatment decision making would benefit from a repeat MRI after neoadjuvant CRT of LARC.

Entities:  

Keywords:  Decision making; Locally advanced rectal cancer; Magnetic resonance imaging; Neoadjuvant therapy

Mesh:

Year:  2020        PMID: 31054106     DOI: 10.1007/s12029-019-00246-5

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  26 in total

1.  Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer.

Authors:  N K Kim; M J Kim; S H Yun; S K Sohn; J S Min
Journal:  Dis Colon Rectum       Date:  1999-06       Impact factor: 4.585

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis.

Authors:  M J Lahaye; S M E Engelen; P J Nelemans; G L Beets; C J H van de Velde; J M A van Engelshoven; R G H Beets-Tan
Journal:  Semin Ultrasound CT MR       Date:  2005-08       Impact factor: 1.875

4.  Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  F De Felice; A L Magnante; D Musio; M Ciolina; C N De Cecco; M Rengo; A Laghi; V Tombolini
Journal:  Eur J Surg Oncol       Date:  2017-03-23       Impact factor: 4.424

Review 5.  Evolving Treatment Paradigm in the Treatment of Locally Advanced Rectal Cancer.

Authors:  Clayton A Smith; Lisa A Kachnic
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

6.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Lisa Gurski; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

7.  Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases.

Authors:  Sam Hee Kim; Ki Beom Bae; Jung Min Kim; Jae Ho Shin; Min Sung An; Tae Geun Ha; Sung Mok Ryu; Kwang Hee Kim; Tae Hyeon Kim; Chang Soo Choi; Jin Yong Shin; Minkyung Oh; Seung Hun Baek; Kwan Hee Hong
Journal:  J Korean Soc Coloproctol       Date:  2012-04-30

8.  Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment.

Authors:  Monique Maas; Doenja M J Lambregts; Patty J Nelemans; Luc A Heijnen; Milou H Martens; Jeroen W A Leijtens; Meindert Sosef; Karel W E Hulsewé; Christiaan Hoff; Stephanie O Breukink; Laurents Stassen; Regina G H Beets-Tan; Geerard L Beets
Journal:  Ann Surg Oncol       Date:  2015-07-22       Impact factor: 5.344

9.  Locally advanced rectal cancer: Qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy.

Authors:  Pietro Valerio Foti; Giuseppe Privitera; Sebastiano Piana; Stefano Palmucci; Corrado Spatola; Roberta Bevilacqua; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Gaetano Magro; Giovanni Li Destri; Pietro Milone; Giovanni Carlo Ettorre
Journal:  Eur J Radiol Open       Date:  2016-07-18

10.  Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.

Authors:  Claudio Belluco; Marco Forlin; Matteo Olivieri; Renato Cannizzaro; Vincenzo Canzonieri; Angela Buonadonna; Ettore Bidoli; Fabio Matrone; Giulio Bertola; Antonino De Paoli
Journal:  Ann Surg Oncol       Date:  2016-08-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.